AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Lexicon Pharmaceuticals I... (LXRX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.73

-0.01 (-1.51%)

At close: Feb 20, 2025, 3:59 PM

0.73

-0.16%

After-hours: Feb 20, 2025, 05:50 PM EST

undefined% (undefined)

Bid	0.73
Market Cap	264.36M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.74
PE Ratio (ttm)	-0.99
Forward PE	n/a
Analyst	Buy

Ask	0.74
Volume	2,350,716
Avg. Volume (20D)	4,958,205
Open	0.74
Previous Close	0.74
Day's Range	0.72 - 0.76
52-Week Range	0.62 - 2.83
Beta	undefined

About LXRX

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The compan...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 7, 2000

Employees 285

Stock Exchange NASDAQ

Ticker Symbol LXRX

Website https://www.lexpharma.com

Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for LXRX stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 446.97% from the latest price.

Buy 50.00%

Hold 50.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Lexicon Pharmaceuticals Inc. is scheduled to release its earnings on Mar 10, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

-8.4%

Lexicon Pharmaceuticals shares are trading lower a... Unlock content with Pro Subscription

11 months ago

+29.49%

Lexicon shares are trading higher after the company said it is preparing to resubmit its Sotagliflozin NDA for Type 1 diabetes following FDA feedback. Additionally, the company announced a securities purchase agreement expected to result in gross proceeds of around $250 million.

News

2 months ago · reuters.com

US FDA declines to approve Lexicon Pharma's add-on diabetes drug

The U.S. Food and Drug Administration declined to approve Lexicon Pharmaceuticals' add-on drug for type 1 diabetes and chronic kidney disease, the company said on Friday.

3 months ago · reuters.com

Lexicon Pharmaceuticals to cut workforce by 60% to focus on drug development

Lexicon Pharmaceuticals said on Friday it would reduce its workforce by about 60%, effective Dec. 31, to eliminate commercial activities and focus on drug development.